[資料]製薬各社製品売上(世界):L-O行

 Medical Letter日本語版では、参考データとして市場データを調査しているが、
 代表的な製薬企業のAnnual Reportから製品売上の部分を抜粋したものをここで掲載する。

■個別製薬会社


★A-F行
★G-K行



Abbott
アボット ジャパン
Agouron Pharmaceuticals →see Pfizer
　Agouron Pharmaceuticals, Incは、
Warner-Lambertに買収された[1999.5]。
　その後Pfizerは、Warner-Lambertを
吸収合併した(2000.6.19)。 関連記事
　現在Agouron独自のWeb-siteはない。
TAP Pharmaceutical Products Inc.[US]
　〜米Abbottと武田薬品のJV
Abraxis BioScience Inc.
ACADIA Pharmaceuticals Inc[US]
Acorda Therapeutics Inc[米国]
Actelion Ltd[スイス]　■新薬ベンチャー
アクテリオン　ファーマシューティカルズ　ジャパン株式会社
Adams Laboratories Inc.[US]〜呼吸器疾患薬専門メーカー
Aderis Pharmaceuticals
AEterna Zentaris Inc.[Ca]　■バイオ医薬
　--Zentaris GmbH[GE]
Affymax, Inc.
Akorn, Inc.〜眼科薬等の専門メーカー
AKZO Novel
N.V. Organon -AKZO Novel子会社
日本オルガノン
Alcon Laboratories,Inc.　■医療機器
日本アルコン　■医療機器
Alfa Wassermann S.P.A.[伊]
Alkermes, Inc.[US]
Allergan
アラガン
Almirall Prodesfarma, S.A.[SP]
Alpharma Inc.
Alseres Pharmaceuticals, Inc(旧Boston Life Sciences, Inc.)
Altana AG
Altana Pharma AG[旧Byk-Gulden AG]　医薬事業2007.1→Nycomed
Alza Corporation - J&J子会社
American BioScience, Inc.[ABI,ABS]　→ Abraxis BioScience Inc.
American Pharmaceutical Partners, Inc. (APP)　→ Abraxis BioScience Inc.
Amersham
Amersham Health(旧 Nycomed Amersham Imaging)
アマシャム バイオサエインス株式会社
日本メジフィジックス株式会社
Amgen
アムジェン
Amylin Pharmaceuticals, Inc
AstraZeneca
アストラゼネカ
Aventis　合併→Sanofi-Aventisヘ
Aventis Pharmaceuticals Inc.[US]
アベンティスフアーマ（株）
Aventis Behring
　→変更ZLB Behring [旧]Aventis Behring(2004.5変更)
　→ see CSL Limited[オーストラリア]の傘下に
アベンティス ベーリング ジャパン株式会社
　→ZLBベーリング株式会社
 [旧]アベンティス ベーリング ジャパン株式会社(2004.5変更)
Aventis Pasteur　2005.1社名変更→Sanofi Pasteur SA[FR,ワクチン]
Aventis Pasteur -US　2005.1社名変更→Sanofi Pasteur Inc. -US[US,ワクチン]
アベンティスパスツール　→サノフィパスツール[旧アベンティスパスツール]
Dermik Laboratories[US] ★Aventis子会社
Avigen, Inc[US]　■新薬ベンチャー
Barr Laboratories Inc.
Bausch & Lomb　■医療機器
ボシュロム・ジャパン株式会社　■医療機器
Baxter Healthcare Corp　■医療機器
バクスター株式会社　■医療機器
Bayer AG
バイエル薬品
Beaufour-IPSEN →Ipsen Group[FR]
Becton, Dickinson and Company　■医療機器
日本ベクトンディッキンソン 　■医療機器
Bertek Pharmaceuticals Inc[US]〜Mylan Laboratories,Inc.の子会社
Biocodex[FR]
Biogen IDEC Inc.[2003.11 Biogen/IDEC合併]
BioMarin Pharmaceutical Inc.[US]　■新薬ベンチャー
bioMerieux SA[FR]　■診断薬
bioMerieux Inc.[US]　■診断薬
日本ビオメリュー株式会社　■診断薬
Boehringer Ingelheim
日本ベーリンガーインゲルハイム
旧Boston Life Sciences, Inc.　→Alseres Pharmaceuticals, Inc
Bristol-Myers Squibb[BMS]
ブリストル・マイヤーズ株式会社
Bryan Corporation[US]
Altana Pharma AG ←[旧Byk-Gulden AG]　医薬事業2007.1→Nycomed
Cambridge Laboratories Ltd[UK]〜ベンチャー
Celgene Corporation[US]
Celltech Group[英国]〜バイオ企業2004.7 UCBにより買収
Cell Therapeutics, Inc.[US]〜制癌剤ベンチャー
Centocor - Johnson & Johnson傘下
Cephalon Inc
Chiron　→Novartis子会社に(2006)
CollaGenex Pharmaceuticals, Inc.
Ciba Vision Corporation[Novartis系列]
チバビジョン[Novartis系列]
CSL Limited[オーストラリア]
CSL Behring[米]
ＣＳＬベーリング株式会社
ZLB Behring [旧]Aventis Behring(2004.5変更)　→CSL Behring[米]
Aventis Behring　→CSL Behring[米]
ZLBベーリング株式会社
 [旧]アベンティス ベーリング ジャパン株式会社(2004.5変更)　→ＣＳＬベーリング株式会社
Cubist Pharmaceuticals, Inc.　■新薬ベンチャー
CV Therapeutics, Inc[US]
Debiopharm SA[SZ]　■新薬ベンチャー
Dermik Laboratories[US] ★Aventis子会社
DEY, L.P
Dusa Pharmaceuticals, Inc.[US]〜新薬ベンチャー
ECR Pharmaceuticals[US]
Elan Corporation, plc[IR]　■新薬ベンチャー
Endo Pharmaceuticals Inc.[US]〜神経系薬剤専門メーカー
Enzon Pharmaceuticals, Inc〜■新薬ベンチャー
Eyetech Pharmaceuticals, Inc.[US] →2005.11 OSI Pharmaceuticals, Inc.[US]に買収
Grupo Ferrer Internacional, S.A[スペイン]
Ferring Pharmaceuticals[スイス]
FibroGen, Inc.
First Horizon Pharmaceutical Corporation[US]〜■新薬ベンチャー　→Sciele Pharma, Inc.
Forest Laboratories, Inc.
Fournier Pharma[FR]



Galderma S.A.[仏] ...L'Oreal & Nestleの50:50合弁会社[設立1981]
L'Oreal[仏]
Galen Holdings Plc[アイルランド]
　　社名変更→Warner Chilcott, Inc.[米国](旧Galen Holdings Plc→2004)
Gedeon Richter Ltd[HU]
Genentech, Inc - Roche傘下
General Electric Company[GE]
GE Health
Genome Therapeutics Corporation[US]　
合併→　Oscient Pharmaceuticals Corporation[US]　■新薬ベンチャー
Genzyme Corporation
ジェンザイム・ジャパン
Gilead Science
Glaxo SmithKleine[GSK]
グラクソ・スミスクライン
Graceway Pharmaceuticals LLC[米]
Grunenthal GmbH[独]
Guilford Pharmaceuticals Inc.[米]〜新薬ベンチャー　→2005.10 MGI Pharma,Inc[米国]〜新薬ベンチャーに買収
Helsinn Healthcare SA[スイス]
Hollister-Stier Laboratories[US]
Hospira,Inc
ホスピーラ・ジャパン
Laboratoire HRA Pharma[仏]
Institut Biochimique SA[IBSA]-[SZ]
ICOS
Lilly-ICOS
Immunex★2001.12 Amgenによる買収に合意。
Imclone Systems Inc.　新薬ベンチャー
Idenix Pharmaceuticals,Inc[旧Novirio Pharmaceuticals, Inc]　新薬ベンチャー
Indevus Pharmaceuticals, Inc.
INOTECH Biotechnologies Ltd.
Ikaria
INO Therapeutics
InSite Vision Inc[US]
Insmed Inc.[US]　新薬ベンチャー
Inspire Pharmaceuticals Inc　新薬ベンチャー
Intendis GmbH(Schering AGの外用薬専門子会社)
Institut Biochimique SA[IBSA]-[SZ]
Intermune Inc.〜■新薬ベンチャー
Ipsen Group[FR]
Isis Pharmaceuticals, Inc.〜■バイオベンチャー
IVAX Corporation[US]
Jerini AG[独]〜新薬バイオ企業
Johnson & Johnson
Centocor - J&J傘下
Janssen - J&J傘下
ヤンセン ファーマ株式会社
McNeil Consumer & Specialty Pharmaceuticals　[J&J 系列]
Ortho-McNeil, Inc　[J&J 系列]
Ortho-McNeil Pharmaceutical, Inc　[J&J 系列]
Ortho-McNeil Neurologics, Inc　[J&J 系列]
OrthoNeutrogena - Ortho-McNeil Pharmaceuticals, Inc.のスキンケア事業部門
Vistakon Pharmaceuticals　[J&J系列]
Johnson & Johnson Vision Care,Inc　[J&J系列]
Tibotec, Inc.[Division of Ortho Biotech Products, LP]
King Pharmaceuticals Inc.[US]　■新薬ベンチャー
KV Pharmaceutical Company[US]
　■急成長の技術重視型ジェネリック企業






★L-O行
★P-Z行



LEO Pharma A/S
Leo Japan
LG Life Science[韓国]
Ligand Pharmaceuticals Inc[米]
Lilly
日本イーライリリー
L'Oreal[仏]
Lundbeck A/S
Madaus AG[独]
Mallinckrodt Group Inc.
 [Tyco International Ltd〜医療機器]子会社
Meda AB
The Medicines Company[米]〜新薬ベンチャー
Medicis Pharmaceutical Corporation[US]〜外用薬専門
MediGene AG[独]
Medimmune
日本メジフィジックス株式会社
MedPoint Pharmaceuticals Inc[US][旧Carter-Wallace, Inc.]　(2007.8買収、社名変更)→Meda AB
Medtronic,Inc[US]　■医療機器
Menarini[IT]
Merck & Co.
Merck KGaA
メルク株式会社
メルク製薬株式会社[旧メルク・ホエイ株式会社]　→マイラン製薬
Merck Sante SA[FR]
Lipha SA[FR]
Merck-Serono S.A.[スイス][旧Serono S.A.]
EMD Serono, Inc[旧Serono USA]
メルクセローノ株式会社
Merz Pharmaceutische GmbH
MGI Pharma,Inc[米国]〜新薬ベンチャー
Millennium Pharmaceuticals, Inc[US]〜新薬ベンチャー
3M [Minnesota Mining & Manufacturing Co.]
3M Healthcare
3M Pharmaceuticals　(2007)→米国事業はGraceway Pharmaceuticals Incへ/欧州事業はMeda AB(米MedPointe Pharmaceuticalsの親会社)へ
住友スリーエム株式会社
Mission Pharmacal Company
Mundipharma AG[瑞]
Mylan Laboratories,Inc.[US]
Mylan Pharmaceuticals,Inc.[US]
Bertek Pharmaceuticals Inc[US](閉鎖2006)〜Mylan Laboratories,Inc.の子会社
マイラン製薬
DEY, L.P〜Mylan Laboratories,Inc.の子会社
Novavax ,Inc.[US]
Novartis
ノバルティス ファーマ株式会社
Novartis Ophthalmics AG
Novartis Ophthalmics International
Novartis Ophthalmics US
Ciba Vision Corporation[Novartis系列]
チバビジョン[Novartis系列]
Speedel Holding Limited[スイス]/Speedel Pharmaceuticals Inc.(2008.7 Novartis 61.44%)
Novo-Nordisk
ノボノルディスクファーマ
N.V. Organon -AKZO Novel子会社
日本オルガノン
NPS Pharmaceuticals,Inc[US]　■新薬ベンチャー
Nycomed[DE]
Odyssey Pharmaceuticals,Inc.[Pliva米国子会社]
Onyx Pharmaceuticals 
Orion Group[FI]
Orphan Europe sarl[FR]
Orphan Medical, Inc[米国]　■新薬ベンチャー
Oscient Pharmaceuticals Corporation[US]　■新薬ベンチャー
  (1994　Collaborative Research Inc→Genome Therapeutics Corporationに社名変更
  (2004　Genesoft Pharmaceuticals社を吸収合併→Oscient Pharmaceuticals に社名変更)
OSI Pharmaceuticals, Inc.[US]〜新薬バイオ企業
Ovation Pharmaceuticals, Inc[US]　■新薬ベンチャー



Pfizer
ファイザー株式会社
Pharmacia★2003.4.16 Pfizer社に経営統合。
ファルマシア・ジャパン★2003.8.1 ファィザー（株）に統合
Pharmion Corporation[米]〜新薬ベンチャー
Photocure ASA[NO]
Laboratoires Pirre Fabre[仏]
Pliva d.d.[Croatia]
Odyssey Pharmaceuticals,Inc.[Pliva米国子会社]
Praecis Pharmaceuticals,Inc[US]　■新薬ベンチャー
Presutti Laboratories, Inc.[US]　■新薬ベンチャー
Procter &Gamble
Prometheus Laboratories Inc[US]
Protein Design Labs, Inc.[US]
Purdue Pharma L.P.[US]
Purdue Pharmaceutical Products L.P.　→　Purdue Pharma L.P.[US]グループ
Purdue Products L.P.　→　Purdue Pharma L.P.[US]グループ
The Purdue Frederick Company　→　Purdue Pharma L.P.[US]グループ
QLT Photo Therapeutics[Ca]
Q-Med AB[SW]　■ヒアルロン酸
Reckitt Benckiser plc[UK]家庭用品〜旧Reckitt & Colman plc
RECORDATI IND.CHIMICA FARM. S.P.A[IT]
Repros Therapeutics Inc.[US]
Roche
日本ロシュ→★中外製薬に統合
Genentech, Inc - Roche傘下
Roche Diagnostics
ロシュ・ダイアグノスティックス株式会社
Salix Pharmaceuticals, Inc[米国]〜消化器官用薬専門メーカー
Sanofi-Aventis
Sanofi-Synthelabo　↑現Sanofi-Aventis
Sanofi-Synthelabo[US]
サノフィ・サンテラボ・ジャパン
Sanofi Pasteur SA[FR,ワクチン]
Sanofi Pasteur Inc. -US[US,ワクチン]
Santhera Pharmaceuticals Ltd.[瑞]
Savient Pharmaceuticals, Inc.[米]
Schering AG
日本シェーリング株式会社
Berlex[US] - Schering AG 子会社
Intendis GmbH(Schering AGの外用薬専門子会社)
Schering-Plough
シェリング・プラウ
Schwarz Pharma AG[ドイツ]
Sciele Pharma, Inc.
Sepracor Inc.[US]
Serono S.A.　→Merck-Serono S.A.[スイス][旧Serono S.A.]
Merck-Serono S.A.[スイス][旧Serono S.A.]
EMD Serono, Inc[旧Serono USA]
セローノ・ジャパン　→メルクセローノ株式会社
Servier[FR]
日本セルヴィエ株式会社
Shire Pharmaceuticals Group plc[UK]〜新薬ベンチャー
SkyePharma PLC[英]
Smith & Nephew plc[UK]　■医療製品
Solvay S.A.
Unimed Pharmaceuticals, Inc.[Solvayの子会社]
Somerset Pharmaceuticals, Inc[US]
 - Mylan Labs)とWatson Pharmaceuticals, Incの合弁会社[50:50]
Speedel Holding Limited[スイス]/Speedel Pharmaceuticals Inc.(2008.7 Novartis 61.44%)
SuperGen, Inc.[米]
Tercica, Inc.
Teva Pharmaceutical Industries Ltd.[イスラエル]
Tibotec, Inc.[Division of Ortho Biotech Products, LP]
Tillotts Pharma AG[SZ]〜消化器病薬専門メーカー
Transkaryotic Therapies, Inc.(TKT)[US]　■新薬ベンチャー
Trimeris
Tyco International Ltd〜医療機器
Tyco Healthcare
Mallinckrodt Group Inc.
タイコヘルスケア・ジャパン株式会社
日本シャーウッド株式会社
UCB
ユーシービージャパン
Unimed Pharmaceuticals, Inc.[Solvayの子会社]
United Therapeutics Corporation[US]　■バイオ新薬ベンチャー
Valeant Pharmaceuticals International[旧ICN]
Vernalis Group plc[英国]
Vicuron Pharmaceuticals,Inc.[US] 旧Versicor　■新薬ベンチャー
VIVUS, Inc[US]
Warner Chilcott, Inc.[米国](旧Galen Holdings Plc→2004)
Watson Pharmaceuticals Inc
Wyeth
ワイス（株）
ZLB Behring
 [旧]Aventis Behring(2004.5変更)
　→ see CSL Limited[オーストラリア]の傘下に
Zentaris GmbH[GE]
  →親会社AEterna Zentaris Inc.[Ca]　■バイオ医薬
ZLBベーリング株式会社
 [旧]アベンティス ベーリング ジャパン株式会社(2004.5変更)
　→ see CSL Limited[オーストラリア]の傘下に

■LEO Pharma A/S

  Leo Pharma A/Sは、Leo Foundationの資本支配下にある中核企業。
  Leo Groupの2005年度売上　DKK 4,856.5 millio
　従業員数3,012

●売上

M DKK
2005
2004
2003
2002
2001
Turnover - 合計
4,856.50
4,741.40
4,540.30
4,425.80
4,105.30
Turnover -中止事業
111.2
427.4
427.6
434.6
434.9
Turnover -継続事業計
4,745.30
4,314.00
4,112.70
3,991.20
3,670.40
Turnover -継続事業(DK外)
4,467.30
4,110.90
3,921.40
3,821.10
3,530,9
Result from primary activities 
1,722.60
1,063.70
1,432.70
1,414.00
1,156.20
Net financials 
789.2
436.8
444.3
350.2
269.5
経常利益
2,511.80
1,500.50
1,877.00
1,764.20
1,425.50
特別損益
0
0
0
0
87.3
税引き前利益
2,511.80
1,500.50
1,877.00
1,764.20
1,512.90
純利益
1,966.30
1,148.80
1,434.30
1,352.60
1,154.50
従業員数
3,012
3,313
3,346
3,336
3,275






●Leo Pharma A/S

 --- http://www.leo-pharma.com/w-site/leo/docs.nsf

●Financial Figures

●News Room
 - 2006 | 2005 | 2004 | 2003 |2002 |2001
The annual result 2005[2006.3.28]

●Product


●Pipeline



●Innohep

 --- http://www.innohep.com/ ; 2002.4.18 WEB Site設置
 --- US Prescribing Information

■LG Life Science[韓国]

 - http://www.life.lg.co.kr/ ; LG Chem子会社。　ハングル語ページのみ



●LG Life Science[韓国]

 - http://www.life.lg.co.kr/ ; LG Chem子会社。　ハングル語ページのみ
GeneSoft acquires antibiotic rights[2002.10.23]
 - Factive(gemifloxacin mesylate)は、LG Life Science社[韓国]で開発され、GSKに
ライセンスされたが、2000年にFDAがGSKに non-approvable letter を発行したため、
権利はLGに戻された。

   [Oscient との契約地域]
North America,France, Germany, the United Kingdom, Luxembourg, Ireland, Italy,
 Spain, Portugal, Belgium, the Netherlands,
Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland,
 Andorra, Monaco, San Marino and Vatican City.

Ligand Pharmaceuticals Inc[米]

■Ligand Pharmaceuticals Inc.

1987.9　Progenx, Inc.として創立。
1991    Ligand に社名変更。
1997      Ligand はONTAKの米国の権利を$67 million で獲得。(LillyはSeragen社への研究費支出により権利を保持していた)
1998.8.12 Ligand社はSeragen, Incを買収($30 million)。　1998.8申請のONTAK(TM) (denileukin diftitox)を獲得した。
1999.3    Ferrer Internacionalと抗腫瘍薬(Ontak, Panretin gel, oral Panretin, Targretin gel, and Targretin capsules)の
		Spain, Portugal, and Greece as well as Central and South America 地域の独占販売権を契約。
2000.1    Alfa WassermannとOntak, Panretin gel,Panretin capsules and Targretin gel and capsules の５製品の
		イタリーでの独占販売権を契約。
2001.12   ElanからOnzar の欧州申請に伴い1.0 million を受領。2001.3 抗腫瘍薬５製品の英独仏を含む北部欧州の独占販売権を契約。
2006.9.6  Ligandは King社にAVINZA売却。($280.4 million in net cash )
2006.9.7  Eisai Inc., a Delaware corporation and Eisai Co., LtdにOncology Product Line を売却。
　　　　　即ちONTAK, Targretin capsules, Targretin gel and Panretin gel.($185.0 million in net cash )
Ligand Pharmaceuticals Cl B: Information from Answers.com
Ligand Exercises Final Option to Buy Down ONTAK Royalties[2005.4.7]
Sample Marketed Drug Report Format - New Medicine's Oncology 


($ 000)
2007
2006
2005
2004
2003
2002
2001
備考
製品売上高
-
0
旧136,983
112,793
旧166,081
69,470
旧120,335
16,482
旧55,324
1,114
旧30,326

旧32,038

Royalty
11,409
-
-
-
-
-

Royalty権売上
-
-
-
31,342
11,786
17,600

共同研究等の収入
1,485
3,977
10,217
旧10,527
11,300
旧11,835
13,698
旧14,008
23,533
旧23,843

旧30,718

　収入合計
12,894
3,907
旧140,960
10,217
旧123,010
112,112
41,966
42,247

製品原価
-
0
旧22,642
0
旧23,090
18,264
12,383
2,579

研究開発費
44,623
41,546
旧41,926
30,710
旧33,096
30,742
旧32,720
28,302
旧29,649
37,109

販売及び一般管理費
30,410
43,908
旧79,748
23,134
旧56,168
12,580
旧46,431
12,059
旧34,776
18,645

　原価及び経費合計
75,033
85,454
53,844

営業利益
(60,175)
(78,080)
旧(168,770)
(43,627)
旧(21,845)
(680)
旧(15,380)
(14,877)
旧(44,202)
(16,086)

継続事業営業利益
(34,759)
(56,590)
旧(135,859)
(36,035)
旧(31,470)
2,684
旧(22,764)
(24,566)
旧(64,474)
(24,445)

中止事業
316,447
24,847
旧104,116
(364)
旧(4,929)
(47,825)
旧(22,377)
(69,900)
旧(29,992)
(27,812)

当期純利益
281,688
(31,743)
(36,399)
(45,141)
(96,471)
(52,257)

従業員数[連結]
59
122
493
519
461


AVINZA
18,256
136,983
112,793
69,470
16,482
旧66,200
1,114
旧12,174
-
[morphine sulfate 徐放性カプセル]米承認2002.3米発売2002.6
ONTAK
-
26,588
30,996
32,200
24,108
旧34,343
17,706
旧26,642
24,298
[denileukin diftitox]CD25陽性皮膚浸潤性Ｔ細胞リンパ腫(CTCL);FDA承認1999.2.5
Targretin capsules
-
17,575
18,692
15,105
11,556
旧10,077
8,563
旧12,188
14,571
[bexarotene]再発性皮膚浸潤性Ｔ細胞リンパ腫(CTCL)米承認1999.12、欧発売2001.3
Targretin gel 
and Panretin gel
-
3,349
3,600
3,560
3,178
旧4,012
2,943
旧3,518
6,754
Targretin gel(bexarotene)皮膚Ｔ細胞リンパ腫(CTCL)米承認2000.6
Panretin Gel(alitretinoin)AIDS随伴表在性カポジ肉腫;米承認1999.2,欧発売2000.10
製品売上高　計
18,256
184,495
166,081
120,335
55,324
旧114,632
30,326
旧54,522
45,623
[]
うちOncology
-
47,512
53,288
[]
[]


2006.10.25 Oncology事業をEisai, Incに売却。(ONTAK, Targretin capsules, Targretin gel, and Panretin gel)
2007.2.26  AVINZA事業をKing Pharmaceuticals, Incに売却


*ONTAK 売上高(2003)34.3 million 
[製品売上高]
AVINZAの売上高
[Royalty売上]
Royalty Pharma AG と2002.3と３製品のselective estrogen receptor modulator (SERM) に関してに契約。
うち２製品はPfizer and Wyethとの共同開発。
[共同研究等の収入]
GlaxoSmithKline　−Promacta (also known as eltrombopag) P3 /SB-559448(thrombocytopenia治療薬) P1
Wyeth  - Viviant (also known as bazedoxifene). NDA申請
Pfizer　−Oporia (also known as lasofoxifene)  NDA申請
TAP    - LGD2941 ,selective androgen receptor modulator (SARM)
Lilly  - LY674 ,動脈硬化薬　P2

■Investor Relations

●Press Releases

●SEC Documents
Form 10-K[2008.3.5]
Form 10-K[2007.3.16]
Form 10-K[2006.3.31]

★2007年度末(売却事業分は2005年末)

製品
適応
段階
備考
●AVINZA
Chronic, moderate-to-severe pain
米発売

●ONTAK
CTCL
米発売1999.2；MAA withdrawn(ONZAR)

Chronic lymphocytic leukemia(CLL)
Phase II

B-cell Non-Hodgkin's lymphoma
Phase II

Peripheral T-cell lymphoma
Phase II

NSCLC third line 
Phase II

Psoriasis (severe)
Phase II保留

●Targretin capsules
CTCL
米発売2000.1、欧発売2001Q4

NSCLC first-line
Phase III

NSCLC monotherapy
Phase II/III

NSCLC second/third line
Phase II/III

Advanced breast cancer
Phase II

Renal cell cancer
Phase II

Psoriasis (moderate to severe)
Phase II保留

●Targretin gel
CTCL
米発売2000.9；MAA withdrawn2002

Hand dermatitis (eczema) 
Phase II/III

Psoriasis
Phase II

●Panretin gel
Kaposi's sarcoma
米発売1999.2

LGD1550 (RAR agonist) 
Advanced cancers
Phase II

Acne
Pre-clinical

Psoriasis
Pre-clinical

LGD-4665 (Thrombopoietin oral mimetic)
Idiopathic Thrombocytopenia Purpura, myelodysplastic syndrome, Hepatitis C, other thrombocytopenias 
Phase II

製品
適応
段階
販売権保持
LGD-2941 (Androgen antagonist)
Osteoporosis, frailty and sexual dysfunction
(SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMs) )
Phase I
TAP
Eltrombopag (TPO agonist)
Thrombocytopenia (Idiopathic Thrombocytopenic Purpura, ITP) 
申請(短期ITP)
P3(長期ITP)
GlaxoSmithKline
Thrombocytopenia (hepatitis C) 
Phase III
GlaxoSmithKline
Thrombocytopenia (Chemotherapy-Induced, CIT)
Phase I/II
GlaxoSmithKline
Thrombocytopenia (hepatic, renal, CITs)
Phase I
GlaxoSmithKline
SB-559448 (TPO agonist)
Thrombocytopenia
Phase I
GlaxoSmithKline
Bazedoxifene (Viviant)
Osteoporosis prevention and treatment
申請
Wyeth
Bazedoxifene CE (Aprela)
Osteoporosis prevention/Vasomotor symptoms
Phase III
Wyeth
Lasofoxifene (1) 
Osteoporosis prevention, vaginal atrophy
申請
Pfizer
Osteoporosis treatment
申請
Pfizer



(1)  In September 2005 and February 2006, respectively, Pfizer announced receipt
 of non-approvable letters from the FDA for the prevention of osteoporosis and
 vaginal atrophy.  




●ONTAK(R)
【概要】ONTAK is a fusion protein that represents the first of a new class of targeted cytotoxic biologic agents. Rights to ONTAK were acquired from Eli Lilly in 1997 and in the acquisition of Seragen in 1998. ONTAK is marketed in the U.S. for patients with CTCL, which affects approximately 16,000 people in the U.S. In addition to ongoing CTCL trials, we have conducted, or are conducting clinical trials with ONTAK in patients with CLL, peripheral T-cell lymphoma, B-cell NHL, NSCLC, and GVHD, indications that represent significantly larger market opportunities than CTCL. 
1997      Ligand はONTAKの米国の権利を$67 million で獲得。(LillyはSeragen社への研究費支出により権利を保持していた)
1998.8.12 Ligand社はSeragen, Incを買収($30 million)。　1998.8申請のONTAK(TM) (denileukin diftitox)を獲得した。
1999.3    Ferrer Internacionalと抗腫瘍薬(Ontak, Panretin gel, oral Panretin, Targretin gel, and Targretin capsules)の
		Spain, Portugal, and Greece as well as Central and South America 地域の独占販売権を契約。
2000.1    Alfa WassermannとOntak, Panretin gel,Panretin capsules and Targretin gel and capsules の５製品の
		イタリーでの独占販売権を契約。
2001.12   ElanからOnzar の欧州申請に伴い1.0 million を受領。2001.3 抗腫瘍薬５製品の英独仏を含む北部欧州の独占販売権を契約。
2006.9.7  Eisai Inc., a Delaware corporation and Eisai Co., LtdにOncology Product Line を売却。
　　　　　即ちONTAK, Targretin capsules, Targretin gel and Panretin gel.($185.0 million in net cash )

[CTCL Market]
 CTCLにおける競合はNipent(Supergen/Abbott)及びInterferon(Intron A等)
 CTCL患者数は、米16,000人、欧12,000-14,000人と推定。
 ONTAK, Targretin capsules&GelはCTCL治療薬として承認。
 ONTAKは米国で1999.2発売だが、この１０年で初のCTCL治療薬。欧州はCTCLで2001.12申請したが、2003.4取下げ。
追加試験を要望されたが次世代ONTAK開発を優先したため。
【2005】 In early 1999, ONTAK entered Phase II trials for the treatment of patients with NHL. NHL affects approximately 300,000 people in the U.S. and Ligand estimates that more than 50,000 of these patients would be candidates for ONTAK therapy. One multicenter study conducted by the Eastern Cooperative Oncology Group (ECOG) assessed ONTAK in patients with certain types of low-grade B-cell NHL who have previously been treated with at least one systemic anti-cancer treatment. The study results were presented at ASCO 2005 and showed the efficacy of ONTAK in patients with small cell lymphocytic lymphoma. A second multicenter trial evaluated ONTAK in 54 patients with relapsed/refractory low or intermediate grade lymphoma. The results of this study are being analyzed and are expected to be presented in 2006. 

     Separately, a Phase II study of ONTAK in 45 patients with relapsed/refractory B-cell NHL was conducted by researchers from the MD Anderson Cancer Center and published in 2004 in the Journal of Clinical Oncology. The study enrolled late-stage, heavily pretreated patients (median of 4 prior treatments) and showed that 25% of the patients achieved a complete or partial response and an additional 20% achieved stabilization of disease. Furthermore, this study showed that ONTAK could be administered in patients with low blood platelet counts, a patient population that cannot tolerate treatment with chemotherapy or radio-immunotherapy. On the basis of these favorable findings, two Phase II studies of ONTAK in relapsed/refractory B-cell lymphoma were launched in 2004. One multicenter trial conducted by Ligand is evaluating ONTAK on a weekly regimen in patients with poor blood platelet counts at entry and another study conducted by investigators at MD Anderson Cancer Center is evaluating ONTAK plus Rituxan(R) (a monoclonal antibody marketed for the treatment of relapsed low grade lymphoma) in patients who have failed prior treatment with Rituxan. The interim results of the latter study were presented at ASH in 2005. Of the 39 patients enrolled, 36 are evaluable for response. The overall response rate was 33.3% and another 19% had stable disease. All of the responders but four had disease refractory to previous rituximab treatment. The objective response rate in the subset of patients with relapsed/refractory follicular lymphoma was 64%. Based on these favorable results, Ligand plans to launch two new studies of ONTAK plus rituximab in this patient population. 


Investigators at MD Anderson Cancer Center also conducted a Phase II study on ONTAK in relapsed/refractory T-cell NHL. The final results of this study, which enrolled a total of 26 patients, were presented at ASH in 2005, which showed an overall 50% response rate. Of the 13 patients whose tumors positively expressed the CD25 component of the IL-2 receptor, 61.5% showed a complete or positive response. The other 13 patients, which were not positive for CD25, showed a response rate of 45%. We are also conducting a multicenter Phase II study of ONTAK plus a chemotherapy regimen designated as CHOP as first line treatment of patients with T-cell NHL. Although the CHOP chemotherapy regimen is considered as the standard of care for patients with T-cell NHL, about 50% of patients fail to achieve a complete response and, of those who respond, over 50% relapse within 2 years. The trial is designed to demonstrate whether the addition of ONTAK to CHOP will increase the response rate and the duration of response. Interim results of the trial are expected in 2006. Additional studies are being planned to better define the role of ONTAK in combination with chemotherapy in the treatment of newly diagnosed and relapsed T-cell NHL. 


     ONTAK is also being evaluated to treat CLL, which affects more than 60,000 people in the U.S. Researchers from Wake Forest University conducted a multicenter Phase II study of ONTAK in patients with CD25-positive CLL who have failed prior treatment with fludarabine. The results of this pilot study were published in the journal Clinical Cancer Research in 2003 and showed that ONTAK reduced CLL in blood cells, lymph nodes and bone marrow. In the study, nine of 10 patients who received at least three courses of ONTAK experienced reductions in peripheral CLL cells, with three of these patients showing reductions of at least 99%. In addition, six of 10 patients showed reductions in the diameter of their cancerous lymph nodes, with one patient showing an 80% reduction. One of 12 evaluable patients showed a partial remission, with 80% node shrinkage and 100% clearance of CLL cells from bone marrow. Based on these encouraging results, three multicenter Phase II studies were launched in 2003 to further evaluate the role of ONTAK in patients with relapsed/refractory CLL. Preliminary results from one study of 16 patients conducted by investigators from Wake Forest University were reported at ASH in 2004 , and showed there was a 27% response rate among the 11 evaluable patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. The investigators concluded that ONTAK “has activity in CLL with toxicities that can be managed with adequate premedication and close monitoring.” The final results of this study and another study conducted by the Hoosier Oncology Group are expected to be published in 2006. The Company conducted a third trial which is nearing completion. 


     Clinical trials with ONTAK have demonstrated benefits in patients with steroid-resistant acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation. One Phase I-II study conducted by investigators from the Dana Farber Cancer Center in Boston enrolled 30 patients and the results were published in the journal Blood in 2004. The study established a dose of ONTAK that is safe in this patient population and showed that ONTAK resulted in a 71% response rate. Another multicenter Phase I-II study conducted by investigators from the Texas Transplant Institute enrolled 21 patients and the results were published in the journal Biology of Blood and Marrow Transplantation in 2005. The study confirmed that ONTAK can be safely administered in this patient population and that ONTAK achieved a 47% response rate at Day 36 of treatment with an additional 31% of patients achieving a response by Day 100. On the basis of these promising results, a randomized 4-arm study is being conducted by the Bone Marrow Transplant Network with NCI funding to evaluate the efficacy and safety of ONTAK and three other investigational agents in the primary treatment of acute GVHD. 


     A multicenter Phase II study exploring the use of ONTAK as a monotherapy for patients with relapsed/refractory advanced NSCLC was conducted by investigators from the University of Cincinnati and completed in late 2004. The preliminary study results reported at the American Society of Clinical Oncology (ASCO) meeting in May of 2005 showed that ONTAK resulted in an unconfirmed partial response or disease stabilization in 40% of patients and noted an association between disease stabilization and an increase in a subset of T-lymphocytes in the circulation, suggesting that ONTAK’s effect could be ascribed to an activation of the immune system. These findings were consistent with the results of a study conducted by investigators from Duke University and presented at an oral session at ASCO in 2004 which showed that ONTAK significantly activated the immune system in patients with solid tumors receiving ONTAK in combination with an investigational anti-tumor vaccine. 
【2003】The increase in ONTAK(R) sales in 2003 compared to 2002 reflects price increases and increasing use (impacted in part by expanded clinical data) in CTCL, chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL) and graft-versus-host disease (GVHD). Overall demand for ONTAK(R) measured by unit shipments to end users, increased 22% for 2003 compared to the prior year. Sales of Targretin(R) capsules also benefited from a 14% increase in prescriptions in 2003 compared to the prior year. Targretin(R) capsules sales were negatively impacted, however, by management decisions to better balance wholesale inventories through reductions of product at two major customers. Additionally, sales of ONTAK(R) and Targretin(R) capsules were negatively impacted by increased chargebacks and rebates reflecting changes in our patient mix and evolving reimbursement rates. We continue to study recently enacted changes to the 2004 Centers for Medicare and Medicaid Services reimbursement rates (ONTAKR) and Section 641 of the Medicare Prescription Drug Improvement and Modernization Act relating to anti-cancer drugs (Targretin(R) ). Early assessments indicate a much improved patient access for Targretin(R) capsules and increased challenges for a small sub-segment of our ONTAK(R) /Medicare patients in 2004 and 2005.


        The increase in ONTAK(R) sales in 2002 compared to 2001 reflects price increases, further penetration of private oncology practices and a higher level of use for indications where the product may be effective but for which registration clinical trials have not been completed and for which FDA approval has not yet been granted. These indications include chronic lymphocytic leukemia (CLL), B- and T-cell non-Hodgkins Lymphoma (NHL) and graft-versus-host disease (GVHD). Likewise, demand for Targretin(R) capsules in 2002 benefited from growing prescriptions for treatment of non-small cell lung cancer (NSCLC) as well as increased use in CTCL.


●Targretin(R) capsules 
米国承認1999.12、発売2000.1。 １日１回経口投与で患者に便利。
　ECは2001.3承認,2001Q4発売。　NSCLCの適応拡大は申請準備中
【】


●Targretin(R) gel
　米国承認2000.6、発売2000.9。再発性 早期CTCLに非侵襲性の治療手段を提供。
　欧州は、CTCLで申請2001.3、取り下げ2002。
【】


●Panretin(R) gel カポジ肉腫
MAA=2000,欧発売2001Q4
【】


●AVINZA(R) (２種のmorphine配合；即効性および24H徐放性)
FDA承認=2002.3 ,発売2002.6
 (for the once-daily treatment of moderate-to severe pain in patients who require continuous,
 around-the-clock opioid therapy for an extended period of time.)
本剤はElanが開発し、1998年に当社に米国・カナダの権利をライセンス。
The U.S. sustained-release opioid marketは2004年度約$4.1 billion。
2003年初め、Organon社と共同販売契約を締結。
AVINZA prescription market share for 2006 was 3.7% compared to 4.4% for 2005

【】


●PROMACTA(R) (eltrombopag)

【2007】Eltrombopag is an oral, small molecule drug that mimics the activity of thrombopoietin, a protein factor that promotes growth and production of blood platelets. Eltrombopag is a product candidate that resulted from our collaboration with SmithKline Beecham (now GlaxoSmithKline). At the European Hematology Association meeting on June 9, 2007, GlaxoSmithKline announced positive Phase III data showing increased platelet count and significantly lower incidence of bleeding in patients with Idiopathic Thrombocytopenia Purpura (ITP). GlaxoSmithKline submitted a New Drug Application, or NDA, for approval to market eltrombopag (PROMACTA TM /REVOLADE TM ) on December 18, 2007. Two pivotal trials, one Phase III trial and one Phase II trial, were submitted to support the NDA submission. On March 3, 2008, the United States Food and Drug Administration (FDA) accepted for filing and review GlaxoSmithKline’s NDA and granted a priority review status for PROMACTA(R) (eltrombopag) for treatment of chronic short-term ITP. Priority review is granted by the FDA for a treatment that addresses significant unmet medical needs or has the potential to provide a significant improvement compared to marketed products, and results in a review period of six months from the date of NDA submission. If approved, PROMACTA would be the first oral thrombopoietin receptor agonist therapy for the short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding. Eltrombopag is currently in a Phase III trial for the long-term treatment of ITP. GlaxoSmithKline reported positive Phase II data in patients with thrombocytopenia associated with hepatitis C and initiated two Phase III trials in patients with hepatitis C in the fourth quarter of 2007. A Phase II study in patients with chemotherapy-induced thrombocytopenia has been completed and a Phase I study is ongoing in patients with sarcoma receiving the adriamycin and ifosfamide regimen. 




●

【】



●

【】

■Lilly

2007.1.29  LillyはICOS Corporationの全株を取得。 
2008.8.20  SGX Pharmaceuticals社を買収完了(6400万ドル)、米バイオ〜最先端構造生物学を生かした医薬品開発
2008.10.14 ImClone Systems社を買収開始





●会社決算

($ milllion)
2007
2006
2005
2004
2003
2002
2001
2000
売上高
18,633.5
15,691.0
14,645.3
13,857.9
12,582.5
11,077.5
11,542.5
原価
4,248.8
3,546.5
3,472.2
3,223.9
2,675.1
2,176.5
2,160.2

販売・管理費
6,095.1
4,889.8
4,497.0
4,284.2
4,055.4
3,424.0
3,417.4
研究開発費
3,486.7
3,129.3
3,025.5
2,691.1
2,350.2
2,149.3
2,235.1

取得研開費
745.6
-
-
392.2
-

経常利益
3,876.8
3,418.0
2,717.5
2,941.9
3,261.7
3,457.7
3,506.9

純利益
2,953.0
2,662.7
1,979.6
1,810.1
2,560.8
2,707.9
2,780.0
従業員数
40,600
41,500
42,600
旧50,800
44,500
旧52,400
45,000
旧54,600
42,900
旧56,200
57,700



[2008.10]★イーライリリー社は、ペンシルベニア州東部連邦検事による進行中の
「ジプレキサ(R)」調査、および32州とコロンビア特別区にまたがるジプレキサ関連調査
の解決に関連して、合計14億7700万ドルの費用を計上した。 from 2008年第3四半期の業績報告




■売上
●製品売上

($ milllion)
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
備考
★神経系
Prozac/Sarafem
315.1(-31)
453.4(-19)
559.0(-13)
645.1(-12)
733.7(-63)
1990.0(-23)
2,573.7(-1.5)
2,613.4(-7)
-
fluoxetine うつ病
　　米国
152.8
249.1
327.3
399.4
　　国外
162.3
204.3
231.7
245.7
Zyprexa
4,761.0(+9)
4,363.6(+4)
4,202.3(-5)
4419.8(+3)
4276.9(+16)
3688.9(+20)
3086.6(+31)
2,349.5(+24.6)
1,885.0(+31)
-
olanzapine　精神分裂
　　米国
2,236.0
2,106.2
2,034.9
2422.2
2645.5
　　国外
2,525.0
2,257.4
2,167.4
1997.6
1631.4
Strattera
569.4(-2)
579.0(+5)
552.1(-17)
666.7(+80)
370.3
2.6(-)
-
-
-
-
(atomoxetine)ストラテラ/ADHD治療薬(米国発売2003.1)
　　米国
464.6
509.2
498.7
656.4
369.9
　　国外
104.8
69.8
53.4
10.3
0.4
Cymbalta
2,102.9(+60)
1,316.4(+94)
679.7(-)
93.9
-
-
-
-
-
-
(duloxetine HCl)うつ病、糖尿病性神経障害
　　米国
1,835.6
1,158.7
636.2
92.7
-
　　国外
267.3
157.7
43.5
1.2
-
Symbyax
-
53.9(-23)
70.2
-
-
-
-
-
-
(olanzapine and fluoxetine HCl)双極性うつ病
　　米国
52.6
70.1
-
　　国外
1.3
0.1
-
★糖尿病、内分泌
Humulin
985.2(+6)
925.3(-8)
1,004.7(+1)
997.7(-6)
1060.4(+6)
1004.0(-5)
1061(-4.8)
1,114.5(+2)
1,090.0(+13)
964
human insulin[rDNA origin]
　　米国
365.2
367.9
410.7
422.7
521.9
　　国外
620.0
557.4
594.0
575.0
538.5
Humalog
1,474.6(+13)
1,299.5(+9)
1,197.7(+9)
1101.6(+8)
1021.2(+22)
834.2(+33)
627.8(+79)
350.2(+56)
224.5(+73)
-
lyspro-insulin
　　米国
888.0
811.0
739.6
685.4
662.7
　　国外
586.6
488.5
458.1
416.2
358.6
Actos
370.6(-17)
448.5(-9)
493.0(+9)
452.9(+5)
431.2(+10)
391.7(+9)
361(+62)
223.0
Q3発売
-
[pioglitazone]米国販売権2006.9迄
　　米国
150.8
279.1
355.7
340.4
362.4
　　国外
219.8
169.4
137.3
112.5
68.8
Humatrope
440.8(+6)
415.6(+0)
414.4(-4)
430.3(+16)
370.9(+13)
329.3(+5)
313(+4.1)
300.7(+0.2)
300.0(+12)
267
somatropin
　　米国
213.6
202.3
184.5
204.8
167.0
　　国外
227.2
213.3
229.9
225.5
203.9
Byetta
330.7(+51)
219.0(-)
39.6
[exenatide] from Amylin;GLP-1様Incretinsはインスリン分泌亢進および血糖降下作用を持つが、本剤はincretin mimetic agentとして２型糖尿病適応の皮下注a 39-amino acid peptide amide
　　米国
316.5
219.0
39.6

　　国外
14.2
-
-

★癌
Gemzar
1,592.4(+13)
1,408.1(+6)
1,334.5(+10)
1214.4(+19)
1021.7(+17)
874.6(+21)
722.9(+29)
559.3(+23)
455.8(+49)
-
gemcitabine
　　米国
670.0
609.8
586.1
561.1
524.2
　　国外
922.4
798.3
748.4
649.3
497.5
Alimta
854.0(+40)
611.8(+32)
463.2(-)
142.6
-
-
-
-
-
-
[pemetrexed]中皮腫、肺癌
　　米国
448.0
350.1
296.3
121.8
-
　　国外
406.0
261.7
166.9
20.8
-
★骨粗鬆症
Evista
1,090.7(+4)
1,045.3(+1)
1,036.1(+2)
1012.7(+10)
922.1(+12)
821.9(+24)
664.8(+27)
521.5(+60)
326.1(+126)
-
raloxifene
　　米国
706.1
664.0
652.9
667.9
660.6
　　国外
384.6
381.3
383.2
344.8
261.5
Forteo
709.3(+19)
594.3(+53)
389.3(+63)
238.6(-)
65.3
-
-
-
-
-
(teriparatide)フォルテオ/骨形成促進剤(FDA承認2002.11.26)
　　米国
494.1
416.2
264.7
198.0
63.2
　　国外
215.2
178.1
124.6
40.6
2.1
★血液凝固阻止剤
ReoPro
-
280.4(-5)
296.7(-18)
362.8(-0)
364.4(-5)
384.0(-11)
431.4(+3)
418.1(-6.5)
447.3(+22)
-
abciximab, Centocor/血管形成術用血液凝固阻止剤
　　米国
-
110.4
119.8
175.4
201.4
　　国外
-
170.0
176.9
187.4
163.0
★消化器
Axid
-
-
-
-
?
?
285(-11.3)
321.4(-9.4)
354.7(-15)
-
[nizatidine]逆流性食道炎;特許2002迄;Reliant Pharmaceuticalsに販売権売却2000.9
★感染症
-
274.6(-38)
443.9(-7)
489.9(-15)
489.9
　　米国
-
25.1
133.3
69.9
110.2
　　国外
-
249.5
310.6
420.0
367.8
Ceclor
-
?
?
232(-18.7)
285.4
?
-
[cefaclor]Dura Pharmaceuticalsが承継[1996.8]→2000.9 Elan Corp.に買収
Vancocin
-
?
?
211(+2.9)
205.0
-
-
[vancomycin]ViroPharmaが承継[2004.10.18]
Xigris
-
192.2(-10)
214.6(+6)
201.8(+26)
160.4(+60)
100.2
-
-
-
-
[drotrecogin alfa (activated)]ザイグリス,敗血症
　　米国
-
103.4
118.9
123.3
110.0
　　国外
-
88.8
95.7
78.5
50.4
★泌尿器
Cialis *1)
1,143.8(-)
215.8(+27)
169.9(+30)
203.3(-)
73.5
-
-
-
-
-
[tadalafil]シアリス/勃起不全(2003)Lilly 73.5/Lilly-ICOS 129.8(発売2003前半/FDA承認2003.11,米国発売03.12)
　　米国
423.8
3.7
2.3
1.4
0.3
　　国外
720.0
212.1
167.6
129.2
73.2
(参考)Cialis世界売上高
1,220
971.0(+30)
746.6(+35)
552.3(+172)

(参考)Lilly ICOS売上
72.7
755.2
プエルトリコを除く北米と欧州
Yentreve
-
-
-
-
-
-
-
-
-
-
[duloxetine HCl]腹圧性尿失禁治療薬（エントレーブ）
★その他医薬品
1,212.3(-12)
1,373.2
旧311.0(-22)
382.2(-21)
485.6(-17)
582.5(-8)
636.2
　　米国
452.3
104.4
91.5
144.5
153.0
　　国外
760.0
206.6
290.7
341.1
429.5

Net sales
18,633.5(+19)
15,691.0(+7)
14,645.3(+6)
13,857.9(+10)
12,582.5(+14)
11,077.5
11,542.5
10,862.2
　　米国
10,145.5
8,599.2
7,798.1
7,668.5
7,221.6
　　国外
8,488.0
7,091.8
6,847.2
6,189.4
5,360.9

●分野別売上高セグメント

Neurosciences
7,851.0
6,728.5
6,080.0
6052.5
5554.8
4668.3
5328.2
5157.6
Zyprexa, Cymbalta, Strattera, Prozac, Permax ,Symbyax, and Yentreve
Endocrinology
5,479.6
5,014.5
4,636.9
4290.9
3926.7
3444.6
3103.5
2583.5
Humalog, Humulin, Actos, Byetta, Evista, Forteo, and Humatrope
旧DiabetesCare
2,960(+6)
-
-
2568.5(+12)
2287.8(+8)
2126.0(+21)
1761.3

Oncology
2,446.4
2,020.2
1,801.0
1366.2
1039.8
893.1
739.1
580.5
Gemzar and Alimta
Animal Health
995.8(+14)
875.5(+1)
863.7(+8)
798.7(+10)
726.6(+5)
693.1(+1)
686.1(3)
627.8(+2)
　国内
480.9
405.9
370.3
338.9

　国外
514.9
469.6
493.4
459.8

Cardiovascular
1,624.1
730.4
旧514.6
778.8
旧608.9
658.7
669.3
624.9
ReoPro and Xigris
Anti-infectives
274.6
443.9(-7)
478.0
489.9
577.4
749.5(-16)
894.3
-
-
[Ceclor,Lorabid,Vancocin]
Other pharm.
236.6
321.9
旧263.1
484.9
旧210.9
212.9
175.4
176.1
342.7
389.9
Cialis, Axid, and other

Net sales
15,691.0
14,645.3
13,857.9
12,582.5
11,077.5
11,542.5
10,862.2


●地区別セグメント
米国
10,145.5
8,599.2
7,798.1
7,668.5
7,221.6
6,582.3
7,364.3
7,002.9
欧州
4,844.5
3,894.3
3,818.6
3,536.2

その他
3,643.5
3,197.5
3,028.6
2,653.2

欧州、中近東、アフリカ
-
-
4,184.0
3,858.4
3,355.8

西欧
-
-
-
3,534.7
3,102.9
2,471.9
1,953.1
1,773.9
その他*新
3,643.5
3,197.5
2,663.2
2,331.0
2,005.1

その他*旧
-
2,654.7
2,258.0
2,023.3
2,225.1
2,085.4 

Net sales
18,633.5
15,691.0
14,645.3
13,857.9
12,582.5
11,077.5
11,542.5
10,862.2

*1) Prior to the acquisition of ICOS, the Cialis sales shown in the table above represent results only in the territories in which we marketed Cialis exclusively. The remaining sales relate to the joint-venture territories of Lilly ICOS LLC (North America, excluding Puerto Rico, and Europe). Our share of the joint-venture territory sales, net of expenses and income taxes, is reported in other income ? net in our consolidated income statement. Subsequent to the acquisition, all Cialis product sales are reported in our net sales.

●Cialis (tadalafil)勃起不全

2008.1.8FDAが1日1回連日服用（2.5mgまたは5mg）「シアリス(R)」（一般名：タダラフィル、経口）を承認した。本用法の「シアリス」を1日1回連日服用すると、男性は服薬のタイミングを気にすることなく性行為を行うことができます。　この低用量・1日1回連日服用の「シアリス」は欧州では既に2007年6月に販売されています。今回の承認により、EDの治療には、症状やライフスタイルにあわせて、１日１回連日服用、あるいは必要に応じて服用する「シアリス」頓用（既に承認されている用法・用量）を選択できるようになりました。

【肺高血圧症】2008.11.17肺高血圧症の適応症の商品化権をUnited Therapeutics Corporation(Nasdaq: UTHR)に導出

●olanzapine(Zyprexa)統合失調症 [2007]

In the second quarter, we submitted NDAs to the FDA and the European Medicines Agency (EMEA) for approval of olanzapine (Zyprexa) long-acting injection. In late February 2008, the FDA issued a “not approvable” letter, stating it needs more information to better understand the risk and underlying cause of excessive sedation events that have been observed in about one percent of patients in clinical trials. Zyprexa, our top-selling product, is a treatment for schizophrenia, acute mixed or manic episodes associated with bipolar I disorder and bipolar maintenance. Zyprexa sales in the U.S. increased 6 percent in 2007, driven by higher net selling prices, partially offset by lower demand. Sales outside the U.S. increased 12 percent, driven by the favorable impact of foreign exchange rates and increased demand. 　販売活動に関して、2004.3に開始したthe Office of the U.S. Attorney for the Eastern District of Pennsylvania (EDPA)による医師に対する支払いを含む調査(Zyprexa, Prozac, and Prozac Weekly)は、2007.11にZyprexaに関する大陪審召喚状を受け取った。　同様の件で2005.6にthe Office of the Attorney General, Medicaid Fraud Control Unit, of the State of Florida、2006.9にはthe California Attorney General's Officから、2007.2にthe Office of the Attorney General of the State of Illinoisから、からZyprexaに関する召喚状。 2006.8にはじまったのは、各州の法務局から消費者保護法関連の召喚状や調査通知で、Zyprexa に関する各種書類が請求されてきた。　カリフォルニア州裁判所ではZyprexaの販売活動がCalifornia False Claims Act違反であるとの訴訟 【ZyprexaのPL法関連訴訟】大半が糖尿病や高血糖の誘因となったとの訴訟。　June 2005以来当社は和解交渉を進めてきており、原告を含めた請求者約31,200人と合意に達した。　1)最初の合意は2005.6に、8,000件の請求に$700 millionを同年中に支払った。　2)2007.1に18,000請求に対して$500 millionを同年中に支払った。　残りの325訴訟(原告1,235人)とは非合意。 2007.10 米最高裁はTeva Pharmaceuticals and Dr. Reddy's Laboratoriesによる特許訴訟を却下。 We have received challenges to Zyprexa patents in a number of countries outside the U.S.: In Canada, several generic pharmaceutical manufacturers have challenged the validity of our Zyprexa compound and method-of-use patent (expiring in 2011). In April 2007, the Canadian Federal Court ruled against the first challenger, Apotex Inc. (Apotex), and Apotex has appealed that ruling. In June 2007, the Canadian Federal Court held that the invalidity allegations of a second challenger, Novopharm Ltd. (Novopharm), were justified and denied our request that Novopharm be prohibited from receiving marketing approval for generic olanzapine in Canada. Novopharm began selling generic olanzapine in Canada in the third quarter of 2007. We have appealed that decision and sued Novopharm for patent infringement. The appeal was dismissed. In November 2007, Apotex filed an action seeking a declaration of the invalidity of our Zyprexa compound and method-of-use patents (expiring in 2011). The trial court ruled in our favor in February 2007. Apotex will likely appeal. . In Germany, generic pharmaceutical manufacturers Egis-Gyogyszergyar and Neolabs Ltd. challenged the validity of our Zyprexa compound and method-of-use patents (expiring in 2011). In June 2007, the German Federal Patent Court held that our patent is invalid. We are appealing the decision. Generic olanzapine was launched by competitors in Germany in the fourth quarter of 2007. . We have received challenges in a number of other countries, including Spain, the United Kingdom (U.K.), and several smaller European countries. In Spain, we have been successful at both the trial and appellate court levels in defeating the generic manufacturers' challenge, but we anticipate further legal challenges from generic manufacturers. In the U.K., a trial date has tentatively been set for July 2008. We are vigorously contesting the various legal challenges to our Zyprexa patents on a country-by-country basis. We cannot determine the outcome of this litigation. The availability of generic olanzapine in Canada and Germany will have a material adverse impact on our consolidated results of operations. The availability of generic olanzapine in additional markets could have a material adverse impact on our consolidated results of operations.

●Cymbalta

【慢性疼痛】慢性疼痛のFDA申請取下げ2008.11.28(2009H1再申請予定);;

【筋線維症】2008.10.24,CHMPが筋線維症の承認否決

【全般性不安障害（GAD）】2008.6.27、CHMPはCymbaltaの全般性不安障害（GAD）の追加適応で承認勧告。　2007.2にFDAは全般性不安障害（GAD）の適応でCymbaltaを承認した。

【2007】 In November, the FDA approved Cymbalta for the maintenance treatment of major depressive disorder in adults. In February, the FDA approved Cymbalta for the treatment of generalized anxiety disorder. During 2007, we submitted a Supplemental New Drug Application to the FDA for Cymbalta for the management of fibromyalgia. Sales of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, and generalized anxiety disorder, increased 58 percent in the U.S., driven primarily by strong demand. Sales outside the U.S. increased 70 percent, driven by increased demand and the favorable impact of foreign exchange rates.

●Strattera ADHD[2007]

Sales of Strattera, a treatment for attention-deficit hyperactivity disorder in children, adolescents, and adults, decreased 9 percent in the U.S., as a result of decreased demand. Sales outside the U.S. increased 50 percent, driven by increased demand and the favorable impact of foreign exchange rates. Actavis Elizabeth LLC (Actavis), Glenmark Pharmaceuticals Inc., USA (Glenmark), Sun Pharmaceutical Industries Limited (Sun), Sandoz Inc. (Sandoz), Mylan Pharmaceuticals Inc. (Mylan), Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex), Aurobindo Pharma Ltd. (Aurobindo), Synthon Laboratories, Inc. (Synthon), and Zydus Pharmaceuticals, USA, Inc. (Zydus) each submitted an ANDA seeking permission to market generic versions of Strattera prior to the expiration of our relevant U.S. patent (expiring in 2017), and alleging that this patent is invalid. We filed a lawsuit against Actavis in the United States District Court for the District of New Jersey in August 2007. Sandoz filed a declaratory judgment action in the same court, but its case has been dismissed. In September 2007, we amended the complaint in the New Jersey lawsuit to add Glenmark, Sun, Sandoz, Mylan, Teva, Apotex, Aurobindo, Synthon, and Zydus as defendants. We filed a second action against Synthon in the United States District Court for the Eastern District of Virginia. Synthon has filed a motion to dismiss our lawsuit in New Jersey. In December 2007, Zydus agreed to entry of a consent judgment in which Zydus conceded the validity and enforceability of the patent and agreed to a permanent injunction. We expect to prevail in this litigation and believe that these claims are without merit. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our consolidated results of operations, liquidity, and financial position.

●Evista 骨粗鬆症[2007]

In September, the FDA approved Evista(R) for a new use to reduce the risk of invasive breast cancer in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer. Sales of Evista, a product for the prevention and treatment of osteoporosis in postmenopausal women and for risk reduction of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, increased 6 percent in the U.S., driven by higher prices. Sales outside the U.S. increased 1 percent, driven by the favorable impact of foreign exchange rates, partially offset by lower prices and lower demand. Barr Laboratories, Inc. (Barr), submitted an Abbreviated New Drug Application (ANDA) in 2002 seeking permission to market a generic version of Evista prior to the expiration of our relevant U.S. patents (expiring n 2012-2017) and alleging that these patents are invalid, not enforceable, or not infringed. In November 2002, we filed a lawsuit against Barr in the U.S. District Court for the Southern District of Indiana, seeking a ruling that these patents are valid, enforceable, and being infringed by Barr. Teva has also submitted an ANDA seeking permission to market a generic version of Evista. In June 2006, we filed a similar lawsuit against Teva in the U.S. District Court for the Southern District of Indiana. The lawsuit against Teva is currently scheduled for trial beginning March 9, 2009, while no trial date has been set in the lawsuit against Barr. We believe that Barr’s and Teva’s claims are without merit and we expect to prevail. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our consolidated results of operations, liquidity, and financial position.

●Forteo [2007]

Sales of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture, increased 19 percent in the U.S., driven by higher net selling prices. U.S. sales growth benefited from access to medical coverage through the Medicare Part D program and decreased utilization of our U.S. patient assistance program and to a lesser extent, increased demand. Sales outside the U.S. increased 21 percent, driven by increased demand and the favorable impact of foreign exchange rates.

●Gemzar [2007]

Sales of Gemzar, a product approved to fight various cancers, increased 10 percent in the U.S., driven by higher prices and increased demand. Sales outside the U.S. increased 16 percent, driven by increased demand and the favorable impact of foreign exchange rates. Sicor Pharmaceuticals, Inc. (Sicor), Mayne Pharma (USA) Inc. (Mayne), and Sun Pharmaceutical Industries Inc. (Sun) each submitted ANDAs seeking permission to market generic versions of Gemzar prior to the expiration of our relevant U.S. patents (compound patent expiring in 2010 and method-of-use patent expiring in 2013), and alleging that these patents are invalid. We filed lawsuits in the U.S. District Court for the Southern District of Indiana against Sicor (February 2006) and Mayne (October 2006), seeking rulings that these patents are valid and are being infringed. In November 2007, the lawsuit against Mayne was stayed and administratively closed by the court. Also in November 2007, Sun filed a declaratory judgment action in the United States District Court for the Eastern District of Michigan, seeking a ruling that our method-of-use patent is invalid or unenforceable, or would not be infringed by the sale of Sun’s generic product. Sun informed us in December 2007 that it is also challenging our compound patent, and that patent has now been added to the declaratory judgment action. In January 2008, we filed a second lawsuit against Mayne in response to a second ANDA filed by Mayne for a new dosage strength. We expect to prevail in this litigation and believe that these claims are without merit. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our consolidated results of operations, liquidity, and financial position.

●Alimta [2007]

Sales of Alimta, a second-line treatment for non-small cell lung cancer and in combination with another agent, for the treatment of malignant pleural mesothelioma, increased 28 percent in the U.S., driven by increased demand and to a lesser extent, higher prices. Sales outside the U.S. increased 55 percent, driven by increased demand and to a lesser extent, the favorable impact of foreign exchange rates.

●Byetta(R)(exenatide) 糖尿病 [2007]

In October, with our collaboration partners Amylin Pharmaceuticals, Inc., and Alkermes, Inc., we announced positive results from a 30-week comparator study of once-weekly exenatide long-acting release injection and Byetta(R)(exenatide) injection taken twice daily in patients with type 2 diabetes. Worldwide sales of Byetta, an injectable product for the treatment of type 2 diabetes, which we market with Amylin Pharmaceuticals (Amylin), increased 51 percent to $650.2 million during 2007. We report as revenue our 50 percent share of Byetta’s gross margin in the U.S., 100 percent of Byetta sales outside the U.S., and our sales of Byetta pen delivery devices to Amylin. Our revenues increased 51 percent to $330.7 million in 2007.

●Humalog, [2007]

ales of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 9 percent in the U.S., driven by higher prices and increased demand. Sales outside the U.S. increased 20 percent, driven by increased demand and the favorable impact of foreign exchange rates, partially offset by declining prices.

●Humulin [2007]

Sales of Humulin, an injectable human insulin for the treatment of diabetes, decreased 1 percent in the U.S., driven by lower demand, partially offset by higher prices. Sales outside the U.S. increased 11 percent, driven by increased demand and the favorable impact of foreign exchange rates, partially offset by lower prices.

●Actos [2007]

Our revenues from Actos, an oral agent for the treatment of type 2 diabetes, a portion of which represent revenues from a copromotion agreement in the U.S. with Takeda Pharmaceuticals North America (Takeda), decreased 46 percent in the U.S. Actos is manufactured by Takeda Chemical Industries, Ltd., and sold in the U.S. by Takeda. Our U.S. marketing rights with respect to Actos expired in September 2006; however, we continue to receive royalties from Takeda through September 2009 at rates that decline each year. Our arrangement outside the U.S. continues. Sales outside the U.S. increased 30 percent, driven primarily by increased demand and to a lesser extent, the favorable impact of foreign exchange rates.

●ReoPro(R)[abciximab]血管形成術用血液凝固阻止剤　発売1995 by Centocor

・血管形成術などの冠状動脈インターベンションを受けている患者の、心虚血性合併症の予防薬 ・ステント手法に伴う不安定狭心症治療薬 (1997) (日本を除き、セントコア社と提携) [Wikipedia]Abciximab

●

●Product pipeline
- Data at April 15,2002
★Late-stage compounds
Actual or anticipated first filing dates for high potential new products

2001 2002 2003 2004
ForteoA Osteoporosis Cialis Male erectile dysfunction Strattera Attention-deficit hyperactivity disorder Cymbalta Depression	OFC Bipolar depression Duloxetine Stress urinary incontinence	Protein Kinase C Beta inhibitor Diabetic retinopathy Macular edema (in Europe) Alimta Mesothelioma	Affinitac NSCLC Resiquimod Genital herpes

AForteo submitted Q4 2000

※Forteo
  ・Lilly Newsroom to search press releases for Forteo
  ・For institutional investors and analysts

※Cialis
  ・Lilly Newsroom to search press releases for Cialis
  ・For institutional investors and analysts
※Strattera -- Atomoxetine
  ・Lilly Newsroom to search press releases for Atomoxetine
  ・For institutional investors and analysts

※Cymbalta -- Duloxetine for depression
  ・Lilly Newsroom to search press releases for Duloxetine
  ・For institutional investors and analysts

※OFC
  ・Lilly Newsroom to search press releases for OFC
  ・For institutional investors and analysts

※Duloxetine for Stress Urinary Incontinence (SUI)
  ・Lilly Newsroom to search press releases for Duloxetine for Stress Urinary Incontinence

※PKC Inhibitor
  ・Lilly Newsroom to search press releases for Protein Kinase C Beta Inhibitor
  ・For institutional investors and analysts

※Alimta
  ・Lilly Newsroom to search press releases for Alimta

※Affinitac (formerly ISIS 3521)
  ・Lilly Newsroom to search press releases for Affinitac

※Resiquimod
  ・Lilly Newsroom to search press releases for Resiquimod



●Eli Lilly

●Products
Diabetes -http://www.lillydiabetes.com/

●Lilly News room

●For investors[決算関連]
★SEC Filngs
10-K Annual Report[2008.2.29] - [pdf] - [xls]
10-K Annual Report[2007.2.28] - [pdf,124p]
10-K Annual Report[2006.3.1] - [pdf,159p] - [xls]
10-K Annual Report[2005.3.8] - [pdf,145p] | [xls]
★Annual reports
Annual Report 2007[pdf,p] - 日本語版[pdf,12p]
Annual Report 2006[pdf,p] - 日本語版
Annual Report 2005[pdf,p] - 日本語版[pdf,]
Annual Report 2004[pdf,100p] -日本語版[pdf,10p]
Annual Report 2003[pdf]
Annual Report 2003 (10-K)[html,Mar 15, 2004][pdf][xls]
Lilly Delivers Outstanding Sales Growth of 17 Percent in the Fourth Quarter[2004.1.29]
Annual Report 2001[html]
Lilly's Fourth Quarter Marks a Return To Quarterly Sales Growth Following Prozac
 Patent Expiration[2003.1.23,html]
Lilly's Fourth Quarter Marks a Return To Quarterly Sales Growth Following Prozac
 Patent Expiration[2003.1.23,pdf:15p]
Product pipeline |日本語　←[Annual report 2000]
Jan 24, 2002 Lilly Announces Fourth-Quarter Earnings per Share of $.60, Excluding One-Time Charges; Company Also Announces Full-Year Normalized Earnings of $2.76 per Share

★Product pipeline





●日本イーライリリー

●くすりと病気の情報
http://www.diabetes.co.jp/[日本Lilly系]
[糖尿病][成長障害][統合失調症][パーキンソン病][がん]
 - 総合失調症 -http://www.schizophrenia.co.jp/
 - http://www.zyprexa.jp/　- 医療関係者のみ、要ID
★くすりの情報
　くすりのしおり/ 医療用医薬品添付文書/ 医療機器添付文書/ 医療機器取扱説明書/ 患者様用注意文書



●最新情報 ---ニュース、年次報告
日本イーライリリー株式会社、2007年度業績と事業展開を発表[2008.3.17]
日本イーライリリー社、2006年業績と事業展開を発表  2006年度総売上　 821億1800万円[2007.3.19]
 -総売上の伸びは薬価ベースで、統合失調症治療剤「ジプレキサ」が11％増の340億円、「ジェムザール」が18％増
の129億円となったことが牽引しました。また、インスリン製品は順当に5％増の141億円、成長ホルモン製剤「ヒュ
ーマトロープ」とパーキンソン病治療薬「ペルマックス」は、薬価改定の影響を受けて、それぞれ4％減の112億円、
15％減の84億円となりました。閉経後骨粗しょう症治療薬「エビスタ」は大きく躍進し、中外製薬と日本リリーの
売上合算で約50％増の180億円超となり、発売2年でトップブランドとなりました。

日本イーライリリー社、2005年業績と事業展開を発表[2006.3.16]
日本イーライリリー社、2004年度総売上 対前年比13.7％増の682億1000万円―営業マーケティング部門が能力開発で受賞、業界屈指のパイプライン―[2005.3.24]

Lilly年次報告2001日本語翻訳版[55p; pdf]
Lilly年次報告2000日本語翻訳版[18p; pdf] |html

米国リリー社2006年度業績 調整後１株当り利益3.18ドル（特別項目除外後）、速報値１株当り利益2.45ドル-第４四半期売上9％増、通期売上7％増-[2007.2.2]
米国イーライリリー社、2005年通期売上　前年比6%増の146億4500万ドル[2006.1.30]
米国イーライリリー社、2004年総売上10％増の138億5800万ドル―新製品売上が15億ドルに倍増―[2005.1.31]
米国イーライリリー社2002年度業績発表[2003.1.22]
米国イーライリリー社2001年度業績発表[2002.1.30]
米国イーライリリー社、長期的戦略を発表長期的な成長を支える有望なパイプラインの
上市時期を示す [2002.11.15]

●「日本の医療・文化に融合」外資系企業のマルチ戦略　７ 　日本イーライリリー
　薬事日報　2003.8.8

　日本イーライリリーの近況では、０１年４月に抗悪性腫瘍剤「ジェムザール」が、従来の非小細胞肺癌に加えて膵癌の追加適応を取得。同年６月に糖尿病治療薬「ヒューマログ」、同じく８月には抗精神病薬「ジプレキサ」を発売し、新製品の３本柱を確立した。これらが寄与して、０１年の売上高は４９４億７３００万円、０２年は６１９億４９００万円を計上した。０１年の売上高の対前年伸び率は業界トップの２７％増、０２年は業界３位の２５％増を示し、わずか２年間で大躍進を遂げた。国内の売り上げランキングも、００年の５２位から０１年には４５位、０２年は３４位とアップした。

　日本での開発状況は、閉経後女性骨粗鬆症治療薬「エビスタ」＝申請中、抗うつ薬「プロザック」＝申請準備中、注意欠落／多動性障害治療薬「ストラテラ」＝第�U相、糖尿病性神経症治療薬（ＰＫＣベータ阻害剤）「ＬＹ３３３５３１」＝第�U相準備中、男性性機能障害治療薬「シアリス」＝第�U相準備。「プロザック」については、厚労省から「プラセボとの比較試験が必要」と要望されており、この課題のクリアも含めて日本で上市するための検討を進めている。

　海外の製品状況は、閉経後女性の確定骨粗鬆症治療薬「フォルテオ」＝米国で昨年１２月発売、６月欧州で承認、「ストラテラ」＝米国で本年１月発売、「シアリス」＝欧州で本年２月発売、米国で本年発売見込み、悪性胸膜中皮腫治療薬「アリムタ」＝米国で０４年発売予定、抗うつ薬（ＳＮＲＩ）「シンバルタ」＝米国で０４年発売予定、難治性抗うつ薬（オランザピンとプロザックの合剤）「シンビアックス」＝米国で０４年発売予定となっている。

　日本イーライリリーの従業員数は１５００人だが、新規採用は昨年３３０人（うちＭＲ２７６人、Ｒ＆Ｄ３９人）、本年２４６人（うちＭＲ１００人、Ｒ＆Ｄ６７人）と積極的な採用が目立つ。今後の計画としては、１０年にＭＲ数１０００〜１１００人、社員数２３００人、国内ランキング１５位を目指す。

●２００２年業績「２５％の増収」　日本イーライリリー 　薬事日報　2003.2.24
　日本イーライリリーの２００２年業績は、売上高６１９億４９００万円で、対前年比２５％の増収となった。

　主力製品は、抗精神病薬「ジプレキサ」、抗癌剤「ジェムザール」、ヒト成長ホルモン「ヒューマトロープ」、インスリン製剤「ヒューマリン」など。営業体制は、５支店、１５分室、ＭＲ７００人。�@内分泌・代謝・骨�A中枢神経�Bオンコロジー――の３領域で、専門ＭＲ制度を導入している。

　今年発売の新薬には「塩酸ラロキシフェン」がある。適応症は閉経後女性の骨粗鬆症を予定しており、中外製薬と共同開発を行っている。上市時期は今年後半を見込んでいる。同剤は選択的エストロゲン受容体モデュレーター（ＳＥＲＭ）と呼ばれる新規化合物で、海外での０２年度売上高は８億ドル以上の実績を示している。

■ICOS

 - http://www.icos.com/
1990年設立; 従業員数675人(2004.12)
2007.1.29  LillyはICOS Corporationの全株を取得。 


●決算

($ 000)
2005
2004
2003
2002
2001
2000
収入
　関連会社協力収入
50,055
56,031
25,943
77,728
54,754
47,404
　ライセンス収入
-
2,200
36,976
6,617
30,846
42,929
　受託製造
16,045
16,377
12,185
8,532
7,402
400
　共同販売収入
5,310
-
-
-
-


　　計
71,410
74,608
75,104
92,877
93,002
90,733

営業費用
　研究開発費
88,289
71,791
85,758
129,350
99,009
82,998
　販売費
42,579
39,392
19,770
9,268
2,741
441
　受託製造コスト
14,028
12,561
9,703
7,599
5,198
81
　一般管理費
20,275
18,247
15,272
16,409
13,795
10,527

　　計
165,171
141,991
130,503
162,626
120,743
94,017

営業利益(損失)
(67,383)
(55,399)
(69,749)
(27,741)
(3,284)

営業外収支
　関連会社損失
-
(130,396)
(87,180)
(104,160)
(64,902)
(37,038)
　関連会社収入
19,519
-
10,000
-
-
-
　支払利息
(6,817)
(6,824)
(3,578)
-
-
-
　受取利息など
6,217
6,355
10,038
12,292
12,470
5,531

　　計
(600)
(130,865)
(70,720)
(91,868)
(52,432)
(31,507)

純損失
(74,842)
(198,248)
(125,507)
(161,617)
(80,173)
(97,866)




●収入内訳

($ 000)
2005
2004
2003
2002
2001
2000
関連会社協力収入
　Lilly-ICOS
50,055
56,031
22,093
6,615
9,965
19,944
　Suncos Corp
-
-
2,450
56,478
30,373
15,175
　ICOS-Texas Biotechnology(ICOS-TBC)
-
-
1,400
14,635
12,676
2,816
　ICOS Clinical Partners,L.P.(ICOS-CP)
-
-
-
-
1,740
9,469

　　計
50,055
56,031
25,943
77,728
54,754
47,404

ライセンス収入
　Lilly-ICOS
-
-
15,031
1,557
29,416
42,331
　ICOS-CP
-
-
-
3,160
981
598
　Biogen
-
-
21,945
1,900
449
-
　その他
-
2,200
-
-
-
-

　　計
-
2,200
36,976
6,617
30,846
42,929

関連会社損益
　Lilly-ICOS
19,519
(130,396)
(87,320)
(65,669)
(38,219)
(23,612)
　Suncos
-
-
140
(29,933)
(15,200)
(7,754)
　ICOS-TBC
-
-
-
(8,558)
(11,461)
(5,476)
　ICOS-CP
-
-
-
-
(22)
(196)

　　計
19,519
(130,396)
(87,180)
(104,160)
(64,902)
(37,038)




●開発品目
tadalafil   - P2 BPH
IC485       - P2 COPD


●ICOS

 - http://www.icos.com/ ;本社Bothell, Washington 98021
2007.1.29  LillyはICOS Corporationの全株を取得。 

●Investor
2006 Form 10K[2006.3.8]
2004 Form 10K[pdf,92p,2005.3.14]

★Press Releases



★Cialis -http://www.cialis.com/








●Lilly-ICOS

 - http://www.lillyicos.com/ →閉鎖
- Lilly /ICOS 50:50の合弁会社

●決算

($ milllion)
2005
2004
2003
2002
備考
収入
610.7
447.9
144.5
-

　Cialis売上高
576.7
421.8
129.8
-

　Cialis Royalty
34.0
26.1
14.7
-
 from Lilly
純損失
37.8
(262.0)
(174.7)
(131.3)


●Cialis売上高

($ milllion)
2005
2004
2003
2002
備考
Lilly-ICOS (北米・欧州)
　米国
272.9
206.6
27.9
*発売2003.11
　欧州
244.5
177.9
95.1
*欧州発売2003.2
　カナダ・メキシコ
59.3
37.2
6.8
*Mexico発売2003.8/Canada-2003.11

　　計
576.7
421.7
129.8

Lilly単独地域
169.9
130.6
73.5


　　合計
746.6
552.3
203.3


*2004年末100か国以上で発売、米国シェア20%;英国23%、フランス43%
*LillyはLilly-ICOSに純売上高の20%のRoyaltyを払う

FROM ICOS 2006 Form 10K[2006.3.8]
FROM ICOS 2004 Form 10K[pdf,92p,2005.3.14]

■Lundbeck A/S

 - http://www.lundbeck.com/
 精神神経系薬剤の専門メーカー。　従業員5,223人[2003末]。

●決算

(DKK milllion)
2007
2006
2005
2004
2003
2002
2001
2000
収入
10,985(+19)
9,221(+2)
9,070(-7)
9,733(-2)
9,941(+5)
9,488
7,656
5,623
営業利益[EBIT]
2,695
1,784
2,170
2,554(+21)
2,147(-10)
2,345
1,826
1,004
経常利益
2,562
1,633
2,242
2,521
2,068
2,058
1,905
1,390
純利益
1,770
1,107
1,574
1,689(+25)
1,384(+8)
1,259
1,323
985
研究開発費
2,187(+12)[20%]
1,958(+10)[21%]
1,782(-)[20%]
1,776(-8)[18%]
1,931[19%]
1,575
1,541

従業員数
5,134
5,111
5,022
5,155
5,223
4,534
3,560


●地域別セグメント
　デンマーク
73.7
238.5
95.3
136.9

　他の欧州
5,504.4
5,103.2
旧5,517.7
5,092.3
4,531.0

　米国
2,652.0
1,957.6
2,633.7
3,825.6

　他の世界
2,754.8
1,921.7
1,507.2
1,248.5
1,239.4






(Eur milllion)
2007
2006
2005
2004
2003
2002
2001
売上高
1,474
1,236

営業利益
362
239

経常利益

当期純利益
238
148

研究開発費
294
262

従業員数[連結]
5,134
5,111
5,022
5,155
5,223
4,534






●売上

(DKK milllion)
2007
2006
2005
2004
2003
2002
2001
2000
1999
備考
Cipramil
-
4,339.6(-16)
5,187.2(+14)
4,539.0
3,454.9(+34)
2,570.9
[citalopram]SSRI-Depression
Cipralex
4,094(+17)[38%]
3,508(+34)
2,625(+58)[29%]
1,661(+157)
645.2(+729)
77.8
*02発売
-
-
[escitalopram]SSRI-Depression /
　　EU
2,827(+10)
2,561
旧2,766(+30)
2,131(+52)
1,404

　　USA
-
-
-
-
-

　　RW
1,267(+34)
948
旧743(+50)
494(+92)
257

Income- Celexa
-
1,724.7(-27)
2,377.5(+44)
1,915.9
1,152.0
511.3
[citalopram]SSRI-Depression
 Lexapro[Forest]米のみ
2,594(+35)[24%]
1,923(-25)
2,552(+5)
2,420(+26)
1,923
旧879
103
-
-
-
(米国発売2002.9)[Escitalopram]
Income - Lexapro
2,594(+35)
1,923(-25)
2,552(+5)[28%]
2,420(+26)
1,927.5(+148)
777.1
259
-
-
[escitalopram]SSRI-Depression /Cipralex
　　EU
-
-
-
1,404(+143)
579
　　USA
2,594(+35)
1,923(-25)
2,552(+5)
2,420(+26)
1,927(+148)
　　RW
-
-
-
257(+287)
66
Ebixa
1,655(+22)[16%]
1,361(+23)
1,105(+53)[12%]
722(+153)
285.9(+893)
28.8
-
-
-
[memantine]アルツハイマー
　　EU
1,359(+20)
1,132
旧1,214(+21)
1,003(+48)
675(+145)
276
　　RW
295(+29)
230
旧147(+44)
102(+118)
47(+380)
10
Azilect
168(+136)[2%]
71(+1,068)
6
-
-
-
-
-
-
[rasagiline]パーキンソン病
　　EU
156(+122)
70
旧71
6
-

　　USA
-
-
-

　　RW
11(+1210)
1
-

Serdolect
34(+250)
10(-)
-
[sertindole]統合失調症
　　EU
24(+247)
7
旧10(-)
-
-

　　RW
11(+257)
3

他の医薬品
1,750(-11)[17%]
1,973(-23)
2,550(-41)[28%]
4,299(-37)
6,818

　　EU
1,135(-16)
1,353
旧1,476(-24)
1,936(+23)
2,511

　　USA
6(-21)
7(-89)
66

　　RW
609(-1)
613
旧489(-11)
547(-32)
807

他の収入
690(+84)[3%]
375(+61)
232(-63)[3%]
631(+139)
264

Other
631(+140)
1,017(-2)
1,040
1,201
1,016
908

●TOTAL収入
10,985(+19)
9,221(+2)
9,070(-7)
9,733(-2)
9,941(+5)
9,488.0
7,655.5
5.622.7(+41)
3,990.6
　　EU
5,501(+7)[50%]
5,123
旧5,537(+9)
5,076(+11)
4,590